JCAR015 Faces Major Impediment, Juno Therapeutics Shares Fall Fast

Finding a cure for cancer is not easy. Seattle-based Juno Therapeutics, a biopharmaceutical company, witnessed a precipitous drop in its stock price after another hold has been placed on its Phase II clinical trial in regards to anti-cancer therapies. [ Content protected for Sovereign Wealth Fund Institute Standard subscribers only. Please subscribe to view content. ]


Contact the writer or creator of this article or page.
Questions or comments: support(at)swfinstitute(dot)org
Follow on Twitter at @swfinstitute and @sovereignfunds
Learn, Attend and Network: Institutional Investor Events and Summits
Go Back: HOME: Sovereign Wealth Fund Institute
 
institutional investor investment mandates